Chukanova E I, Chukanova A S, Mamaeva Kh I
Pirogov Russian National Research Medical University, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(3):57-63. doi: 10.17116/jnevro202112103157.
To study the efficacy and safety of complex treatment with 2-ethyl-3-hydroxy-6-methylpyridine (mexidol forte 250) and venotonic drugs L-lysine aescinat and diosmin/hesperidin in patients with chronic cerebral venous insufficiency (CCVI).
One hundred and twenty CCVI patients with clinical and ultrasonic signs of cerebral venous discirculation were studied. Patients were stratified into group 1 (=40) treated perorally with mexidol forte 250 and diosmin/hesperidin during 74 days in combination with two courses of L-lysine aescinat intravenously on the 1 and 30 days from baseline, group 2 (=40) treated with mexidol forte 250 and diosmin/hesperidin during 74 days, group 3 (=40) treated perorally with diosmin/hesperidin during 74 days.
The efficacy and safety of the complex treatment of CCVI patients with venotonic drugs with the inclusion of mexidol forte 250 at a dose of 750 mg/day for 74 days is shown. The study demonstrates a significant positive effect of mexidol forte 250 on the dynamics of complaints and indicators of the neurological and psychoemotional status of patients. Monotherapy with the venotonic drug diosmin/hesperidin shows its insufficient efficacy.
研究2-乙基-3-羟基-6-甲基吡啶（美西多福250）与静脉张力药物L-赖氨酸七叶皂苷钠及地奥司明/橙皮苷联合治疗慢性脑静脉功能不全（CCVI）患者的疗效和安全性。
对120例有脑静脉循环障碍临床及超声征象的CCVI患者进行研究。患者被分为三组：第1组（n = 40），口服美西多福250及地奥司明/橙皮苷74天，并在基线后的第1天和第30天静脉注射两疗程L-赖氨酸七叶皂苷钠；第2组（n = 40），口服美西多福250及地奥司明/橙皮苷74天；第3组（n = 40），口服地奥司明/橙皮苷74天。
结果显示，采用静脉张力药物联合750毫克/天剂量的美西多福250对CCVI患者进行74天的综合治疗具有疗效和安全性。研究表明，美西多福250对患者的症状动态以及神经和心理情绪状态指标具有显著的积极影响。静脉张力药物地奥司明/橙皮苷单药治疗显示疗效不足。
